A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF LIXIVAPTAN IN PARTICIPANTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE CONSISTING OF A 1-YEAR DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE AND A 1-YEAR OPEN LABEL PHASE: THE ACTION STUDY
- Registry ID
- PA-ADPKD-301
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- PALLADIO BIOSCIENCES, INC.
- Start date
- 2022-01-11
- Last update
- 2021-11-02
Conditions
- AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
Related clinical trials
- A RANDOMISED, DOUBLE BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE, PHASE 1A/1B MULTI-CENTRE STUDY IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF GSK4771261
- MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TWO STAGE STUDY TO CHARACTERIZE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF GZ/SAR402671 IN PATIENTS AT RISK OF RAPIDLY PROGRESSIVE AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD).
- A PILOT STUDY OF CYSTIC VOLUME REDUCTION BY FOAM SCLEROTHERAPY IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
View on source registry